MN-221 Beta-2 Selective Agonist for Asthma Exacerbation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for severe asthma exacerbations, particularly those unresponsive to standard care, often result in inadequate clinical benefits and significant cardiovascular side effects, leading to increased hospitalization rates and prolonged ICU stays.
Innovation Solution
The administration of MN-221, a β2-selective adrenoceptor agonist, intravenously in conjunction with standard respiratory care, provides bronchodilation and reduces hospitalization rates without the cardiovascular side effects associated with traditional β-agonists.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional β-agonists (e.g., albuterol, epinephrine, terbutaline) are administered to treat severe asthma exacerbations, then bronchodilation is achieved, but cardiovascular side effects (tachycardia, palpitations) occur
Solution Approach 1:
The patent applies local quality by designing a β2-selective adrenoceptor agonist that preferentially activates β2-adrenergic receptors in the lungs (local target) while minimizing activation of β1-adrenergic receptors in the heart. This selective receptor binding profile achieves bronchodilation efficacy without the cardiovascular side effects associated with non-selective β-agonists.
Solution Approach 2:
The patent changes the chemical structure parameters of traditional β-agonists to create MN-221 with enhanced β2-selectivity. By modifying molecular characteristics such as the naphthalene ring system and hydroxyl group positioning, the drug achieves higher affinity for β2-receptors relative to β1-receptors, thereby resolving the contradiction between efficacy and side effects.
2Ease of operation
If standard respiratory care (nebulized albuterol, ipratropium, corticosteroids) is used for acute asthma exacerbations, then initial treatment is provided, but patients who fail to respond experience inadequate clinical benefit and increased hospitalization rates
Solution Approach 1:
The patent introduces MN-221 as an intermediary therapeutic agent for patients who do not respond adequately to standard respiratory care. This β2-selective agonist serves as a bridge between conventional treatments and more invasive interventions, providing additional bronchodilation through a different pharmacological mechanism that bypasses the tolerance or resistance issues associated with traditional β-agonists.
3Reliability
If IV or SC adrenoceptor agonists are added to standard of care, then additional bronchodilation may be achieved, but cardiovascular liability increases
Solution Approach 1:
The patent segments the adrenergic receptor system into β1 and β2 subtypes and targets only the β2 subtype for bronchodilation. By administering a highly β2-selective agonist intravenously, the treatment achieves segment-specific therapeutic effect in the lungs while avoiding segment-specific adverse effects in the cardiovascular system that would result from β1 activation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
MN-221 significantly reduces hospitalization rates and improves breathing outcomes in patients with severe asthma exacerbations, achieving a 50% reduction in hospitalization and maintaining improved FEV1 levels for several hours without adverse cardiovascular effects.
Implementation Method 1
MN-221, a β2-selective adrenoceptor agonist
Implementation Method 2
provides additional bronchodilation and improved clinical outcomes
Data Source
AI summary
The invention provides a method of improving one or more clinical outcomes of an individual experiencing an acute respiratory attack. The acute respiratory attack may include acute reversible bronchospasm, severe acute bronchospasm, or acute exacerbation of asthma. The method includes administering to an individual suffering from an acute respiratory attack an effective amount of bedoradrine or a pharmaceutically acceptable salt thereof in combination with a standard of care (SOC) treatment regimen.